EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 25 October 2018

Betting on innovation, the case for the SPC

A blog by Nathalie Moll

This is the third blog telling the story behind the EFPIA Manifesto, we have already explored Health Technology Assessment and transitioning to outcomes-focused health. I would like to dedicate this blog to maintaining and developing Europe’s Intellectual Property (IP) framework, in particular the Supplementary Protection Certificate (SPC).

If we think of the challenges faced by healthcare systems under pressure from an ageing population and increased prevalence of chronic disease, then it is only through innovation leading to new solutions that we will have a chance to create a healthier future for Europe. IP rights and incentives are the foundations of medical innovation.

Read more

Blogs

#ForTheChance to take long mountain walks without the fear of stumbling and fracturing my bones...
19 October 2018

A guest blog from Hanneke, living with fragility fractures caused by Osteoporosis Read more

Value Based Health Care (VBH) Outcomes Workshop: A Health Systems Approach
22 October 2018 - Thomas Allvin

Join us on 15 November 2018 in London to further debate and understand the principles of Value Based Healthcare with... Read more

#WeWontRest until people with rare diseases get faster access to medicines, based on innovative...
15 October 2018

A guest blog by Kim Stratton, Head of International Commercial at Shire Read more

Valued collaborations with patient organizations
23 October 2018

A guest blog by Allan Hillgrove, Member of the Board of Managing Directors, Boehringer Ingelheim Read more

Videos

IMI 10th anniversary video series: The Story of the Innovative Medicines Initiative
Featuring: Rudolf Strohmeier, Director-General of the Publications Office of the European Union and Former Chair... Read more

IMI 10th anniversary video series: IMI Project Participant Testimonial - Academia
Featuring: Prof. Peter Sterk, U-BIOPRED Coordinator, The University of Amsterdam Read more

What we are reading

5 questions for the future of cancer research
On 25 October 2018 (POLITICO)

Personalized medicine makes evaluating new treatments even more difficult. Read more

Does fast-track drugs approval in EU run too fast?
On 25 October 2018 (EurActiv)

More than two years after its launch, the EU’s fast-track approval process for marketing new drugs, called PRIME, is... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu